semaglutide bmi 25 Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) The pounds tumble under incretin-based
Pay in 4 interest-free payments of $5.09 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




























